Caladrius Biosciences, Inc. (CLBS)
Stock Price:
$2.24 USD
0.09 (4.19%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $2.27 +0.03 (1.34%) Aug 14, 7:52 PM
Key Info
| Market Cap |
34.84M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-7.25M |
| Shares Out |
15.55M |
| EPS (ttm) |
-1.81 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$2.24 |
| Previous Close |
$2.15 |
| Change ($) |
0.09 |
| Change (%) |
4.19% |
| Day's Open |
2.33 |
| Day's Range |
2.19 - 2.44 |
| Day's Volume |
932,844 |
| 52-Week Range |
1.05 - 3.64 |
More Stats
| Market Cap |
34.84M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.55M |
| Float |
7.81M |
| EPS (basic) |
-0.83 |
| EPS (diluted) |
-1.81 |
| FCF / Share |
-0.64 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
169,966 |
| Short Ratio |
0.22 |
| Short % of Float |
1.77% |
| Beta |
1.58 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.10 |
| Revenue |
n/a |
| Operating Income |
-18.50M |
| Net Income |
-7.25M |
| Free Cash Flow |
-8.43M |
| Net Cash |
34.89M |
| Net Cash / Share |
2.24 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-38.54% |
| ROE |
-73.77% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.50*
(368.75% upside)
Low
6.00
Current: $2.24
High
18.50
Target: 10.50
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | 22.49 | 17.94 | 14.67 | 14.33 | 10.05 | 69.82 |
| Revenue Growth | - | - | - | - | 25.36% | 22.3% | 2.36% | 42.58% | -85.61% | - |
| Gross Profit | - | - | - | - | 2.33 | 2.26 | 1.72 | 2.38 | 1.40 | 20.15 |
| Operating Income | -20.09 | -16.99 | -27.59 | -29.50 | -114 | -57.74 | -36.81 | -30.39 | -34.00 | -18.88 |
| Net Income | -19.36 | -16.17 | 22.98 | -32.66 | -80.89 | -54.87 | -38.98 | -53.77 | -47.13 | -23.31 |
| Shares Outstanding | 10.33 | 9.69 | 8.97 | 6.55 | 4.85 | 3.28 | 2.05 | 1.38 | 0.89 | 0.52 |
| Earnings Per Share | -1.88 | -1.67 | 2.56 | -4.99 | -16.67 | -16.80 | -19.00 | -40.00 | -54.00 | -46.00 |
| Operating Cash Flow | -18.88 | -19.99 | -20.88 | -23.67 | -39.26 | -46.90 | -27.10 | -13.85 | -20.93 | -8.48 |
| Capital Expenditures | - | -0.13 | -0.14 | -1.10 | -3.19 | -3.66 | -2.69 | -0.53 | -0.57 | -16.38 |
| Free Cash Flow | -18.88 | -20.12 | -21.01 | -24.77 | -42.44 | -50.55 | -29.79 | -14.38 | -21.50 | -24.85 |
| Cash & Equivalents | 25.16 | 43.05 | 60.09 | 7.08 | 20.32 | 26.25 | 46.13 | 13.74 | 3.94 | 18.99 |
| Total Debt | - | - | 0.16 | 6.37 | 16.78 | 16.64 | 4.15 | 3.81 | 3.78 | 12.60 |
| Net Cash / Debt | 25.16 | 43.05 | 59.93 | 0.70 | 3.54 | 9.61 | 41.98 | 9.92 | 0.15 | 6.39 |
| Assets | 27.15 | 44.58 | 63.38 | 53.51 | 57.21 | 126 | 89.82 | 54.41 | 155 | 143 |
| Liabilities | 6.60 | 7.13 | 13.19 | 30.05 | 33.92 | 68.20 | 27.79 | 21.59 | 75.20 | 56.54 |
| Book Value | 20.82 | 37.73 | 50.51 | 4.88 | 23.71 | 58.51 | 62.54 | 33.18 | 62.03 | 48.66 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Caladrius Biosciences, Inc. |
| Country |
United States |
| Employees |
27 |
| CEO |
David J. Mazzo |
Stock Information
| Ticker Symbol |
CLBS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CLBS |
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.